Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar

US global asset managers, including BlackRock, have expanded stakes in mainland Chinese pharmaceutical contractor WuXi AppTec over the past two months, betting that a surge in weight-loss drug manufacturing orders will lift earnings in the first half of the year. Global investors